{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:56:40Z","timestamp":1785427000323,"version":"3.56.0"},"reference-count":14,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Analyzing how mutations affect the main protease of SARS-CoV-2 may help researchers develop drugs that are effective against current and future variants of the virus.<\/jats:p>","DOI":"10.7554\/elife.81334","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T05:00:19Z","timestamp":1658811619000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.81334","source":"Crossref","is-referenced-by-count":2,"title":["Developing evolution-resistant drugs for COVID-19"],"prefix":"10.7554","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1424-7541","authenticated-orcid":true,"given":"Daniel M","family":"Weinreich","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05gq02987","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Ecology, Evolution and Organismal Biology, Brown University","place":["Providence, United States"]},{"id":[{"id":"https:\/\/ror.org\/05gq02987","id-type":"ROR","asserted-by":"publisher"}],"name":"Center for Computational Molecular Biology, Brown University","place":["Providence, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/d41586-021-03619-8","article-title":"Beyond Omicron: what\u2019s next for SARS-CoV-2 evolution?","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1021\/acs.jcim.1c00449","article-title":"Dynamic profiling of \u03b2-coronavirus 3CL Mpro protease ligand-binding sites","volume":"61","author":"Cho","year":"2021","journal-title":"Journal of Chemical Information and Modeling"},{"key":"bib3","article-title":"Coronavirus (COVID-19) Update: FDA authorizes pharmacists to prescribe Paxlovid with certain limitations","author":"FDA","year":"2022","unstructured":"FDA. 2022. Coronavirus (COVID-19) Update: FDA authorizes pharmacists to prescribe Paxlovid with certain limitations. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations [Accessed July 9, 2022]."},{"key":"bib4","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77433","article-title":"Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms","volume":"11","author":"Flynn","year":"2022","journal-title":"eLife"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nmeth.3027","article-title":"Deep mutational scanning: a new style of protein science","volume":"11","author":"Fowler","year":"2014","journal-title":"Nature Methods"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.chembiol.2004.08.010","article-title":"Combating susceptibility to drug resistance: lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chemistry & Biology"},{"key":"bib8","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Communications Biology"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1126\/science.add7226","article-title":"Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug","volume":"377","author":"Service","year":"2022","journal-title":"Science"},{"key":"bib11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nature Communications"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1126\/science.adc9473","article-title":"New versions of Omicron are masters of immune evasion","volume":"376","author":"Vogel","year":"2022","journal-title":"Science"},{"key":"bib13","article-title":"WHO Coronavirus (COVID-19) Dashboard","author":"WHO","year":"2022","unstructured":"WHO. 2022. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int [Accessed July 6, 2022]."},{"key":"bib14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/81334\/elife-81334-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/81334\/elife-81334-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/81334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:25:04Z","timestamp":1697059504000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/81334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":14,"alternative-id":["10.7554\/eLife.81334"],"URL":"https:\/\/doi.org\/10.7554\/elife.81334","archive":["CLOCKSS"],"relation":{},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"e81334"}}